Data compiled by Redley Lamar · ChainSifter Intelligence
5Suppliers
12Customers
2Debt Items
20Related Chains
Source-Backed Evidence Depth
Design Therapeutics, Inc. (DSGN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
20Total relationships
1Distinct source URLs
4High confidence
0.737Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Design Therapeutics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
WISCONSIN-ALUMNI-RESEARCH-FOUNDATION
WISCONSIN-ALUMNI-RESEARCH-FOUNDATION
92%
Under the License Agreement, the Company licensed the exclusive, worldwide, royalty-bearing, sublicensable rights to certain WARF patents and the nonexclusive worldwide rights to certain know-how to …
Reciprocal relationship from LXEO graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from LXEO g…
Reciprocal relationship from PEPG graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from PEPG g…
RNA
Atrium Therapeutics, Inc.
72%
Reciprocal relationship from RNA graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from RNA graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from RNA grap…
Reciprocal relationship from TRDA graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from TRDA graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from TRDA g…
Reciprocal relationship from LLY graph: Reciprocal relationship from DSGN graph: riffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condi…
riffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economi…
Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reaso…
Reciprocal relationship from MYGN graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from MYGN g…
bility of the USPTO and other applicable patent authorities to properly administer their functions is highly dependent on the levels of funding available to the agency and their ability to retain key…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DSGN graph: Reciprocal relationship from SNYN…
SNYNF
Sanofi
72%
bility of the USPTO and other applicable patent authorities to properly administer their functions is highly dependent on the levels of funding available to the agency and their ability to retain key…
Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for sub…
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
offer the disease-modifying potential of genomic therapeutics, while also offering broad tissue biodistribution, resolution of aberrant gene expression preserving endogenous regulatory control elemen…
CELLECT-LLC
CELLECT-LLC
62%
bility of the USPTO and other applicable patent authorities to properly administer their functions is highly dependent on the levels of funding available to the agency and their ability to retain key…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
are unable to obtain PTE or other patent term restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product …
HOFFMANN-LA-ROCHE-AG
HOFFMANN-LA-ROCHE-AG
62%
riffs and trade restrictions remains uncertain and could materially and adversely affect our business, financial condition, and prospects. While we actively monitor these risks, any prolonged economi…
Design Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
DSGN-DEBT-9147
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
DSGN-DEBT
Debt stack $2.7M
90%
Market cache reports total debt of $2.7M.
Design Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Design Therapeutics, Inc..
Design Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
DSGN-OWNER-SR-ONE-CAPITAL-MANAGEMENT-LP
SR One Capital Management, LP
90%
13F overlay lists SR One Capital Management, LP as top holder; 125 tracked holders.
Design Therapeutics, Inc. Extended Supply Chain Network
